Improving depression outcomes through personalized feedback
Improving Outcomes of Depression Through Person-centered Measurement-based Care and Individualized Feedback
This study tests if giving personalized feedback on depression symptoms can help adults with major or persistent depressive disorder feel better and take a more active role in their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 304 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Nova Scotia Health Authority Academic / other |
| Locations | 1 site (Halifax, Nova Scotia) |
| Trial ID | NCT03162211 on ClinicalTrials.gov |
What this trial studies
This project aims to enhance the treatment of depression by implementing a person-centered approach that provides individualized feedback to both patients and clinicians. Adults diagnosed with major depressive disorder or persistent depressive disorder will be randomly assigned to receive regular feedback on their depression symptoms or not. The feedback is designed to empower patients and improve their engagement in their own care. The study seeks to determine if this method can lead to better outcomes in managing depression within the Canadian healthcare context.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with major depressive disorder or persistent depressive disorder.
Not a fit: Patients with a history of bipolar disorder, schizophrenia, current substance use disorders, or acute suicide risk may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve treatment outcomes for individuals suffering from depression.
How similar studies have performed: While similar approaches have shown promise in improving depression outcomes, this specific combination of person-centered care and measurement-based feedback has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * a diagnosis of MDD or PDD established with the Structured Clinical Interview for DSM-5 (SCID-5) * depression being the primary current problem requiring clinical attention judged by an intake clinician * age 18 or more (no upper limit) * capacity to provide informed consent Exclusion criteria: * lifetime diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, current alcohol or drug use disorder * pregnancy * acute suicide risk (Montgomery and Asberg Depression Rating Scales (MADRS) (suicide item≥4) * current psychotic symptoms.
Where this trial is running
Halifax, Nova Scotia
- Nova Scotia Health Authority — Halifax, Nova Scotia, Canada (Recruiting)
Study contacts
- Principal investigator: Rudolf Uher, MD, PhD — Nova Scotia Health Authority
- Study coordinator: Rudolf Uher, MD, PhD
- Email: rudolf.uher@nshealth.ca
- Phone: 1-902-473-7209
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.